End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma

Affiliations

Editorial

Warren P Mason. Neuro Oncol. 2015 May.

. 2015 May;17(5):634-5.

doi: 10.1093/neuonc/nov018. Epub 2015 Feb 13.

¹ Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

No abstract available

Comment on

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA. Nabors LB, et al. Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11. Neuro Oncol. 2015. PMID: 25762461 Free PMC article. Clinical Trial.

1. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22. - PMC - PubMed
1. Bello L, Francolini M, Marthyn P, et al. α(v)B3 and α(v)B5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2):380–389. - PubMed
1. Uhm JH, Dooley NP, Kyritsis AP, et al. Vitronectin, a glioma-derived extracellular matrix protein, protect tumor cells from apoptotic death. Clin Cancer Res. 1999;5(6):1587–1594. - PubMed
1. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs. 2003;4(6):741–745. - PubMed
1. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor cilengitide (EMD121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59(6):1304–1312. - PubMed